CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
of this study is to evaluate the safety, tolerability, and antitumour activity of AZD0754 CAR T-cell therapy in participants with metastatic prostate...
Phase 1, Phase 2
Houston, Texas, United States and 11 other locations
pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy of JANX007 in adults with metastatic castration-resistant prostate ...
Phase 1
Houston, Texas, United States and 25 other locations
The purpose of this study is to investigate potential drug-drug interaction (DDI) between JNJ-56021927 and abiraterone acetate and between JNJ-560219...
Phase 1
Houston, Texas, United States and 6 other locations
The main purpose of this study is to assess the safety and tolerability of AZD0516 as monotherapy and/or in combination with other anti-cancer...
Phase 1, Phase 2
Houston, Texas, United States and 50 other locations
Assessment of the safety and efficacy of HLD-0915 as monotherapy in patients with metastatic castration resistant prostate cancer (...
Phase 1, Phase 2
Houston, Texas, United States and 10 other locations
Medicines that reduce the amount of testosterone in the body are commonly used to treat prostate cancer. PRL-02 depot is a potentia ...
Phase 1
Houston, Texas, United States and 23 other locations
The purpose of this study is to evaluate the effectiveness of CAN-2409 immunotherapy in patients undergoing active surveillance for localized prostate...
Phase 2
Tomball, Texas, United States and 22 other locations
ipilimumab, cabazitaxel and carboplatin in men with neuroendocrine prostate cancer (NEPC) or other aggressive variants of prostate...
Phase 2
Houston, Texas, United States and 2 other locations
Cu 64 PSMA I\&T injection for PET/CT imaging in patients with newly diagnosed unfavorable intermediate high-risk, high-risk or very high-risk prostate...
Phase 3
Houston, Texas, United States and 42 other locations
radiation therapy for patients with intermediate-high risk localized prostate cancer. ProstAtak kills tumor cells and stim...
Phase 3
Houston, Texas, United States and 72 other locations
Clinical trials
Research sites
Resources
Legal